Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma

Overview of attention for article published in Frontiers in oncology, November 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (52nd percentile)
Good Attention Score compared to outputs of the same age and source (77th percentile)

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 3 Dimensions

Readers on

mendeley: 9 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 5 X posts from 4 X users, with an upper bound of 24,595 followers.

RT @FrontOncology: "📄 Improved therapy for choloangiocarcinoma based on Gemcitabine and Cisplatin: preventing the emergence of multidrug re…

02 Jan 2023

Reply Repost Favourite

Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma https://t.co/ShkN817zvo https://t.co/dksV0jlze4

02 Dec 2022

Reply Repost Favourite

"📄 Improved therapy for choloangiocarcinoma based on Gemcitabine and Cisplatin: preventing the emergence of multidrug resistance. 👨‍⚕️👩‍⚕️ Sunisa Prasopporn et al Available here #OpenAccess 👉 https://t.co/jIGvHYBhMf #CancerTreatment #Oncology"

02 Dec 2022

Reply Repost Favourite

#cholangiotwitter #cholangiocarcinoma #bileductcancer #biliarytractcancer

14 Nov 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 1 additional X posts.